AUPH FY2026 EPS Forecast Lifted by Cantor Fitzgerald

Key Points

• Analysts at Cantor Fitzgerald have raised their FY2026 earnings per share (EPS) estimate for Aurinia Pharmaceuticals to $0.74, up from a previous forecast of $0.64.
• Aurinia Pharmaceuticals reported $0.16 EPS for the latest quarter, which was below the consensus estimate of $0.17, despite having a revenue of $70.01 million exceeding expectations.
• HC Wainwright reaffirmed a "buy" rating for Aurinia with a price target of $17.00, while Royal Bank of Canada increased its price target from $8.00 to $9.00.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP - Equities researchers at Cantor Fitzgerald increased their FY2026 earnings per share estimates for shares of Aurinia Pharmaceuticals in a research report issued on Friday, August 1st. Cantor Fitzgerald analyst O. Brayer now anticipates that the biotechnology company will post earnings per share of $0.74 for the year, up from their prior estimate of $0.64. The consensus estimate for Aurinia Pharmaceuticals' current full-year earnings is $0.11 per share.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). The business had revenue of $70.01 million during the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%.

Several other brokerages also recently commented on AUPH. Royal Bank Of Canada boosted their target price on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a research note on Friday, August 1st. HC Wainwright reaffirmed a "buy" rating and set a $17.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 30th.

Aurinia Pharmaceuticals Price Performance

Shares of Aurinia Pharmaceuticals stock traded down $0.20 during midday trading on Monday, hitting $11.42. 1,786,689 shares of the company were exchanged, compared to its average volume of 1,590,286. The firm has a 50 day simple moving average of $8.56 and a 200-day simple moving average of $8.21. Aurinia Pharmaceuticals has a 52 week low of $5.29 and a 52 week high of $11.80. The firm has a market cap of $1.50 billion, a P/E ratio of 26.57 and a beta of 1.23. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63.

Insider Activity at Aurinia Pharmaceuticals

In other news, Director Kevin Tang purchased 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 5th. The shares were acquired at an average price of $11.68 per share, for a total transaction of $2,336,000.00. Following the completion of the acquisition, the director directly owned 11,329,500 shares in the company, valued at approximately $132,328,560. The trade was a 1.80% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last ninety days, insiders acquired 1,300,000 shares of company stock valued at $13,590,000. 12.20% of the stock is currently owned by company insiders.

Institutional Trading of Aurinia Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of AUPH. Invesco Ltd. boosted its position in shares of Aurinia Pharmaceuticals by 1.0% during the fourth quarter. Invesco Ltd. now owns 144,112 shares of the biotechnology company's stock worth $1,294,000 after buying an additional 1,421 shares during the period. GAMMA Investing LLC increased its position in shares of Aurinia Pharmaceuticals by 56.1% in the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock valued at $39,000 after acquiring an additional 1,744 shares during the last quarter. Bridgefront Capital LLC boosted its position in Aurinia Pharmaceuticals by 12.9% during the fourth quarter. Bridgefront Capital LLC now owns 16,606 shares of the biotechnology company's stock valued at $149,000 after purchasing an additional 1,891 shares during the last quarter. Cetera Investment Advisers grew its stake in Aurinia Pharmaceuticals by 3.2% in the fourth quarter. Cetera Investment Advisers now owns 64,638 shares of the biotechnology company's stock valued at $580,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of Aurinia Pharmaceuticals by 20.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 12,989 shares of the biotechnology company's stock worth $110,000 after purchasing an additional 2,238 shares during the last quarter. 36.83% of the stock is owned by institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.